March 17th 2023
In an interview with Targeted Oncology, Yuri E. Nikiforov, MD, PhD, discussed what led to the reclassification of NIFTP and the incidence of thyroid cancer in patients.
February 4th 2023
Brose and Laetsch Discuss Rare Actionable Targets in Patients With Thyroid CancerJanuary 12th 2023
During a Targeted Oncology case-based roundtable event, Marcia S. Brose, MD, PhD, and Theodore W. Laetsch, MD, discussed the data supporting the use of NTRK inhibitors in a patient with metastatic papillary thyroid cancer.
Individualized Care to Prevent Overtreatment and Undertreatment in Thyroid CancerDecember 22nd 2022
In an interview with Targeted Oncology™, R. Michael Tuttle, MD, discussed the plethora of treatment options for thyroid cancer as well as overtreatment and undertreatment of the disease.
Investigators’ Reach Extends Hope for Patients With Anaplastic Thyroid CarcinomaNovember 29th 2022
Advances in thyroid cancer to date hold promise for other orphan cancers with analogous alterations, on which we might bring to bear agents that will have similar effects.
The Road to Overcoming Disparities in Thyroid Cancer CareNovember 20th 2022
In an interview with Targeted Oncology, Megan R. Haymart, MD, provided a recap of a symposium at the American Thyroid 2022 Annual Meeting and discussed disparities in thyroid cancer care, as well as potential solutions
US Surgeons Embrace Radiofrequency Ablation for Thyroid Nodule TreatmentNovember 2nd 2022
In an interview with Targeted Oncology, Jennifer Hong Kuo, MD, discussed the use of radiofrequency ablation to treat thyroid nodules and how research from Columbia University will guide further research around this topic
Cabozantinib Continues to Improve PFS, Regardless of Duration of Previous Lenvatinib Therapy in RAI-Refractory DTCOctober 24th 2022
An extended follow-up of the phase 3 COSMIC-311 trial supported the use of cabozantinib to treat patients with radioiodine-refractory differentiated thyroid cancer, irrespective of the duration of prior lenvatinib received.
Psychiatric History May Prompt Patients’ Decisions for Faster Surgical Treatment in Thyroid CancerOctober 22nd 2022
Psychiatric history may be an important factor for physicians to consider when counseling patients on their treatment options with thyroid cancer, according to a retrospective chart review.
Higher BMI May Induce More Aggressive Disease, Worse Clinical Outcomes in Differentiated Thyroid CarcinomaOctober 21st 2022
Investigators found that higher body mass index is associated with more aggressive differentiated thyroid carcinoma tumors, as well as an increased risk for worse clinical outcomes, with patients with a BMI above 28.4 being at a higher risk.
Real-World Retrospective Review Confirms Efficacy of Frontline Lenvatinib Monotherapy in RAI-Refractory DTCOctober 21st 2022
A real-world retrospective patient chart review showed a 72.4% physician-reported best overall response, confirming the agent’s clinical efficacy to treat patients with RAI-refractory differentiated thyroid cancer.
Cancer Survivors May Be at Increased Risk for Secondary Primary Thyroid CancerOctober 21st 2022
A study found that after their first primary malignancy diagnosis, cancer survivors are at a significantly increased risk for secondary primary thyroid cancer, with other half of cases occurring in the first 3 years.
Significant Increase in Peripheral NK Cells May Support Lenvatinib Efficacy in Advanced Thyroid CancerOctober 21st 2022
A prospective study of blood samples confirmed the immune-modulatory effect of lenvatinib with a significant increase in the peripheral natural killer cells among patients with advanced thyroid cancer.
Withholding RAI Therapy in Low-Risk Pediatric DTC Continues to Yield Comparable Remission RatesOctober 20th 2022
Following American Thyroid Association guidelines, a retrospective study confirmed that remission rates were comparable in pediatric patients with low-risk differentiated thyroid carcinoma who did and did not receive radioactive iodine therapy.
Addition of Atezolizumab to Vemurafenib/Cobimetinib May Improve Survival in BRAF V600E-Mutated ATCOctober 20th 2022
The combination use of a BRAF/MEK inhibitor plus checkpoint inhibitor immunotherapy did not meet median overall survival at 2 years, hinting at the combinations’ improved efficacy in patients with BRAF V600E-mutated anaplastic thyroid cancer.
Lenvatinib/Pembrolizumab Appears Safe in Metastasized Anaplastic Thyroid CarcinomaSeptember 13th 2022
Data presented during the 2022 ESMO Congress showed lenvatinib plus pembrolizumab to elicit an objective response rate of 34.3% after 3 months in evaluable patients, meeting the primary end point of the phase 2 ATLEP trial.
Tweet Chat Recap: Swegal Evaluates a Thyroid Cancer CaseAugust 31st 2022
In an interview with Targeted Oncology following the tweet chat, Warren Swegal, MD, discussed the key takeaways from the discussion, including his thoughts on the case and what he hopes will be addressed in the future of the thyroid cancer space.
Increased Hemithyroidectomy Use in Thyroid Cancer Not Linked With ATA GuidelinesJuly 25th 2022
Focused cancer centers increased hemithyroidectomy 2 years prior to the release of the newest American Thyroid Association guidelines. However, only community cancer program hospitals began to increase hemithyroidectomy utilization following release of guidelines.
Misiukiewicz Describes Decision-Making for NTRK Inhibitors in Thyroid CancerMay 30th 2022
During a Targeted Oncology case-based roundtable event, Krzysztof J. Misiukiewicz, MD, discussed deciding to use NTRK inhibitor for the treatment of a 67-year-old woman with thyroid cancer.
EP. 4B: Understanding Treatment Resistance in First-Generation TRK Inhibitors for the Treatment of NTRK Fusion-Positive CancersMay 13th 2022
In this companion article, David S. Hong, MD, considers the safety and efficacy of the first-generation TRK inhibitor larotrectinib and discusses how acquired resistance may affect research into second-generation agents.